Compare Citius Pharmaceuticals Inc (CTXR) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Illinois Tool Works Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Illinois Tool Works Inc. trades at $293.28 (market cap $83.88B). The key difference: Illinois Tool Works Inc. is far larger — about 4478.4× Citius Pharmaceuticals Inc's market cap, and Illinois Tool Works Inc. pays a 2.34% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | ITW | |
|---|---|---|
Market Cap | $18.73M | $83.88B |
Sector | Health | Industrials |
52-Week High | $1.82 | $299.60 |
52-Week Low | $0.48 | $241.07 |
Enterprise Value | $14.95M | $92.73B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
ITW trades at $296.66, up 0.67% with a bullish technical outlook and strong support at $292. The company maintains robust profitability with 19.39% net margins and has beaten earnings estimates for three consecutive quarters. Recent positive developments include a 7% dividend increase and $6 billion share repurchase authorization announced August 7, 2026.
While valuation metrics appear elevated (P/E 26.87, P/B 29.19), ITW's consistent earnings performance and shareholder-friendly actions support upside to the $316 consensus target. Key risks include construction sector exposure and currency headwinds, but operational strength and margin discipline provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
